Forefront Analytics, LLC Orchard Therapeutics PLC Transaction History

Forefront Analytics, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.36 - $0.49 $23,347 - $31,777	64,853 Added 64.83%	164,894 $61,000
Q3 2022 Nov 14, 2022	BUY	$0.45 - $0.69 $3,330 - $5,106	7,400 Added 7.99%	100,041 $54,000
Q2 2022 Aug 10, 2022	SELL	$0.42 - $0.78 $2,982 - $5,538	-7,100 Reduced 7.12%	92,641 $58,000
Q1 2022 May 09, 2022	BUY	$0.7 - $1.51 $33,022 - $71,234	47,175 Added 89.74%	99,741 $72,000
Q4 2021 Feb 11, 2022	BUY	$1.16 - $2.23 $1,739 - $3,345	1,500 Added 2.94%	52,566 $70,000
Q3 2021 Nov 15, 2021	BUY	$2.24 - $4.29 $75,656 - $144,894	33,775 Added 195.33%	51,066 $118,000
Q2 2021 Aug 10, 2021	BUY	$4.39 - $7.23 $5,184 - $8,538	1,181 Added 7.33%	17,291 $75,000
Q1 2021 May 13, 2021	SELL	$4.39 - $9.08 $70,152 - $145,098	-15,980 Reduced 49.8%	16,110 $118,000
Q4 2020 Feb 12, 2021	BUY	$3.86 - $5.07 $6,643 - $8,725	1,721 Added 5.67%	32,090 $139,000
Q3 2020 Nov 12, 2020	BUY	$4.11 - $6.45 $46,192 - $72,491	11,239 Added 58.75%	30,369 $123,000
Q2 2020 Aug 10, 2020	BUY	$5.75 - $11.99 $109,997 - $229,368	19,130 New	19,130 $115,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

Stay updated on Forefront Analytics, LLC with notifications on news.